Active, not recruitingNCT05438095
Medication Adherence in Patients With Sarcoidosis
Studying Sarcoidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johns Hopkins University
- Principal Investigator
- Michelle Sharp, MD, MHSJohns Hopkins University
- Enrollment
- 150 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (2)
- Johns Hopkins Bayview Asthma and Allergy Center, Baltimore, Maryland, United States
- Johns Hopkins Greenspring Station, Timonium, Maryland, United States
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05438095 on ClinicalTrials.govOther trials for Sarcoidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07498842Corticosteroid Tapering in SarcoidosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07073963Virtual Patient Groups for Sarcoidosis Associated FatigueThe Cleveland Clinic
- RECRUITINGPHASE2NCT07159074Repurposing Tilmanocept for Cardiac SarcoidosisDuke University
- RECRUITINGPHASE2NCT06978725A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)Priovant Therapeutics, Inc.
- RECRUITINGNANCT05954507Evaluation of the Prognostic Value of PET/MRI in Cardiac SarcoidosisAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT06660732Rilonacept in Subjects With Cardiac SarcoidosisMayo Clinic
- RECRUITINGNANCT07384897Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung DiseaseUniversité Catholique de Louvain
- RECRUITINGNCT06510894Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose SuppressionUniversity of Pennsylvania